Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab biosimilar versus Avastin with FOLFIRI3 as first-line therapy for metastatic colorectal cancer
IRCT2015072517994N2Phase 3Completed
- Sponsor
- AryoGen Biopharma
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by AryoGen Biopharma. Primary endpoint: Progression-free survival. Started Oct 2016; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on IRCT2015072517994N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2015072517994N2.